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Abstract. Glioma is one of the most common malignant 
tumor types of the central nervous system. It is necessary to 
identify biomarkers and novel therapeutic targets for glioma. 
The purpose of the present study was to distinguish lipid 
biomarkers with differential expression patterns in glioma 
tissues and normal brain tissues by matrix assisted laser 
desorption/ionization (MALDI)-imaging and MALDI-time of 
flight (TOF)‑mass spectrometry (MS). Additionally, identifi-
cation of lipid biomarkers was performed to describe novel 
therapeutic targets for glioma treatment. A total of six tissues 
from three patients with glioma and three control patients with 
traumatic brain injury were analyzed using UltrafleXtreme 
MALDI‑TOF/TOF. The expression levels of 15 lipid peaks 
were higher in the TBT samples compared with in the GBT 
samples. The expression levels of another 16 lipid peaks were 
higher in the GBT samples compared with in the TBT samples. 
14 peaks were identified as sphingomyelins using MS/MS. 
Additional results were also obtained from experiments using 
the glioma cell line U373-MG. These results indicated that 
treatment with the drug desipramine (Desi) inhibited the 
accumulation of ceramide on the cell membranes of glioma 
U373-MG cells. Treatment with Desi inhibited the activation 
of insulin-like growth factor-1 receptor and inhibited the 
activation of proteins in the PI3K/Akt signaling pathway.
Introduction
Glioma is the most common type of malignant brain tumor 
in adults worldwide (1,2). The principal diagnosis methods 
for patients with glioma include disease history question-
naires, nervous system physical examination and imaging 
examination with different modalities (3). Since early glioma 
prediction and diagnosis is difficult, the majority of patients are 
diagnosed at a late stage. Typically, treatment for patients with 
glioma involves maximal safe surgical resection, followed by 
chemotherapy and radiotherapy. The prognosis of patients with 
glioma is frequently poor due to its aggressive properties (4,5). 
Hence, there is an urgent need to identify novel biomarkers 
for glioma diagnosis and novel therapeutic targets to improve 
patient survival.
Protein and lipid are two types of diagnostic biomarkers 
for glioma (6-8). Biomarkers may be identified from 
patient samples, including serum, cerebrospinal fluid (CSF) 
and glioma cells (9). Capillary morphogenesis protein 2 
(CMG2) has been identified as a prognostic biomarker for 
glioma, and CMG2 increased expression is associated with 
increased tumor grade and poor patient survival (10). The 
effect of protein biomarker T-LAK cell-originating protein 
kinase (TOPK) expression on the outcome in malignant 
glioma has been previously reported, revealing that low 
TOPK expression is an independent predictor of longer 
overall survival (11). Ribom et al (12) performed a compar-
ative proteomics analysis with CSF samples from glioma 
cases and revealed that α-2-Heremans-Schmid glycoprotein 
was highly expressed in the CSF of patients with low‑grade 
disease. Iwadate et al (13) conducted survival predic-
tion research in glioma based on proteomic analysis and 
identified 37 protein biomarkers.
In addition to protein biomarkers, lipid biomarkers are also 
required for the diagnosis and treatment of glioma. The matrix 
assisted laser desorption/ionization (MALDI)-imaging tech-
nique has been widely used in lipid biomarker research (14-16). 
Wildburger et al (15) identified lipids directly from glioblas-
toma tissues by MALDI-imaging mass spectrometry (MS), 
and a number of species of signaling lipids were observed. 
Shrivas et al (17) identified phospholipids in mouse liver and 
cerebellum tissue sections using an ionic matrix for enhanced 
MALDI-imaging MS.
Novel sphingomyelin biomarkers for brain glioma and associated 
regulation research on the PI3K/Akt signaling pathway
XIAO‑HUI ZHAI1,2*,  JIAN XIAO1*,  JIE-KAI YU2,  HONG SUN3  and  SHU ZHENG2
1Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510655; 
2Cancer Institute, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, 
P.R. China;  3Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, NV 89135, USA
Received September 3, 2018;  Accepted July 9, 2019
DOI:  10.3892/ol.2019.10946
Correspondence to: Dr Xiao‑Hui Zhai, Department of Medical 
Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, 
26 Yuancun Erheng Road, Guangzhou, Guangdong 510655, P.R. China
E-mail: zhaixh@zju.edu.cn
Professor Shu Zheng, Cancer Institute, The Second Affiliated 
Hospital of Zhejiang University School of Medicine, 88 Jiefang 
Road, Hangzhou, Zhejiang 310009, P.R. China
E-mail: zhengshu@zju.edu.cn
*Contributed equally
Key words: glioma, matrix assisted laser desorption/ionization- 
imaging, lipid biomarkers, sphingomyelin, PI3K/Akt signaling pathway
ZHAI et al:  NEW BIOMARKERS FOR GLIOMA AND REGULATION RESEARCH ON THE PI3K/AKT PATHWAY6208
In the present study, three glioma brain tissue (GBT) 
samples and three trauma brain tissue (TBT) samples were 
collected to identify lipid biomarkers using MALDI-time of 
flight (TOF)‑tandem mass spectrometry (MS/MS). The lipid 
biomarkers with differential expression were selected and 
identified. The expression of a number of lipid biomarkers 
with potential clinical significance was verified using the 
MALDI-imaging technique. In order to reveal the regulatory 
mechanisms of lipid biomarkers in glioma signaling pathways, 
the glioma cell line U373-MG was cultured, and additional 
research was performed regarding the PI3K/AKT signaling 
pathway.
Materials and methods
Brain tissue samples. In the present study, three GBT samples 
from patients with glioma (two women aged 46 and 55 years and 
one man aged 60 years) and three TBT samples from patients 
with traumatic brain injury (two men aged 48 and 50 years and 
one woman aged 56 years) were collected following neurosur-
gery at The First Affiliated Hospital of Zhejiang University 
School of Medicine (Hangzhou, China) in December 2013. 
Informed consent was obtained from participants for the use 
of their tissues in the present study. All diagnoses of glioma 
were histopathologically confirmed.
Glioma cell culture. The human glioma cell line U373-MG 
was purchased from American Type Culture Collection 
(ATCC). The U373‑MG ATCC cell line is a U‑251 derivative 
according to Cellosaurus (https://web.expasy.org/cellosaurus/
CVCL_2219). It was directly used in the present study without 
additional authentication. The cell line was cultured in DMEM 
(Thermo Fisher Scientific, Inc.), supplemented with 1% peni-
cillin/streptomycin and 10% FBS (Thermo Fisher Scientific, 
Inc.). The cells were grown at 37˚C with 5% CO2 in a humidi-
fied incubator.
Biomarker identification with MALDI‑TOF‑MS/MS. GBTs 
and TBTs were removed from the ‑80˚C freezer and cut into 
10‑µm‑thick sections with a Leica CM950 freezing microtome 
(Leica Microsystems GmbH) at ‑20˚C. Each tissue section was 
pasted on the imaging slide and dried in a vacuum dryer for 
45 min at room temperature. The imaging slide was placed into 
the ImagePrep machine and flushed uniformly with matrix. 
The imaging slide was placed on the MTP Slide Adapter II 
and analyzed with MALDI‑TOF‑MS/MS. The mass scan range 
was set at m/z: 0-3,000. The mass spectrum data were analyzed 
using FlexImaging software version 3.0 (Bruker Daltonics). 
The lipid peaks were identified using MS/MS and results were 
searched in the Human Metabolome Database (18).
Live staining. U373-MG cells were cultured as aforementioned 
in small glass dishes overnight so that they reach 60‑75% 
confluence. Subsequent to removal of the medium, the cells 
were washed once with 500 µl DMEM containing 2% FBS. 
The fluorescent antibody anti-human insulin-like growth 
factor‑1 receptor (IGF‑1R; eBioscience; cat. no. 16‑8849; 
1:20) was added to the DMEM containing 2% FBS. The cells 
were cultured in the new medium with antibody at 37˚C with 
5% CO2 in a humidified incubator for 10 min. The medium 
was discarded and the cells were washed once with DMEM 
containing 2% FBS without antibody. Subsequently, DMEM 
with 2% FBS was added into the dishes. The prepared dishes 
were placed into the CO2 incubator of a laser scanning confocal 
fluorescence microscope. IGF‑1R signal was recorded using 
laser scanning confocal microscopy.
Cell immunostaining. U373-MG cells were cultured in small 
glass dishes as aforementioned. When cells reached 60‑75% 
of the dishes, the medium was discarded and the cells were 
washed once with 1 ml PBS. A volume of 1 ml fixation and 
permeabilization solution (BD Biosciences) was added into 
the dish, which was kept in the dark for 1 h at 4˚C. The fixing 
reagent was discarded and the dish was washed once with 1 ml 
PBS. Goat serum (5%; Jackson Immuno Research) in PBS 
was used for blocking at room temperature for 1 h. The cells 
were incubated with mouse monoclonal primary antibody 
against ceramide (Enzo Life Sciences; cat. no. ALX‑804‑196; 
1:10) at 4˚C overnight. Following three washes with PBS, the 
cells were incubated with goat anti-mouse IgG secondary 
antibody (AF647‑conjugated; Jackson Immunologicals; 
cat. no. 115‑606‑146; 1:300) for 1 h in the dark at room 
temperature. The dish was washed three times with PBS and 
visualized using laser scanning confocal microscopy.
For the regulation of IGF‑1R expression, U373‑MG cells 
were divided into the DMSO and Desi groups. Cells from the 
DMSO group represented the control group and were treated 
with DMSO only and stimulated with insulin for 30 min. 
Cells from the Desi group were treated with the drug Desi and 
stimulated with insulin for 30 min.
Western blotting. The glioma cell line U373-MG was lysed 
with NP40 lysis buffer (Thermo Fisher Scientific, Inc.). The 
protein density in each sample was determined by ultraviolet 
spectrometry and adjusted to the same density using loading 
buffer. Total protein (5 µg) was separated by SDS‑PAGE 
(10% gel) and transferred onto PVDF membranes (EMD 
Millipore). The membranes were blocked at 4˚C overnight 
with blocking buffer (pH 7.6) containing 5% nonfat dried milk 
and incubated with rabbit anti-human monoclonal antibody, 
which was purchased from Cell Signaling Technology, Inc. 
Immunoreactive proteins were stained using a chemilumines-
cent detection system. Membranes were subsequently washed 
with stripping solution for 1 h and treated as aforementioned, 
with mouse β-actin antibody (ProteinTech Group, Inc.) as an 
internal control. The relative target protein expression levels 
were normalized to those of β-actin.
For the regulation of PI3K/Akt pathway, U373‑MG cells 
were divided into the DMSO and Desi groups. Cells from the 
DMSO group represented the control group and were treated 
with DMSO only. Cells from the Desi group were treated with 
the drug Desi. Both groups were then stimulated with insulin 
for 15, 30 and 60 min. Western blot analysis of these samples 
was performed to observe the PI3K/Akt pathway.
Statistical analysis. ClinProTools™ software (version 2.2; 
Bruker Corporation) was used to perform the statistical analysis 
of the peaks. Wilcoxon rank-sum test was used to compare 
data from TBT and GBT groups. Data are presented as the 
means ± standard deviation. Each experiment was repeated 
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three times. P<0.01 was considered to indicate a statistically 
significant difference.
Results
Screening of lipid biomarkers between GBT and TBT samples. 
In the present study, three GBT samples and three TBT samples 
were collected, sliced and analyzed by MALDI‑TOF‑MS. The 
mass spectrum peaks were analyzed using FlexImaging soft-
ware Ver3.0. Increased attention was paid to the differential 
expression peaks of lipid biomarkers in GBT and TBT samples. 
A total of 15 lipid peaks exhibited a higher expression intensity 
in normal control TBT samples compared with GBT samples 
(Table I). Another 16 lipid peaks exhibited a higher expression 
intensity in GBT samples compared with normal control TBT 
samples (Table II).
The expression intensity of the lipid peaks of 798.57, 
722.55, 799.56, 769.58 and 783.79 m/z was markedly 
increased in the TBT samples compared with the GBT 
samples (Table I). Taking the peak of 798.57 m/z as an 
Table I. Lipid peaks with higher expression in TBT samples compared with GBT samples.
Bio-marker (m/z) P-value Expression in TBT (mean ± SD) Expression in GBT (mean ± SD)
798.57 <1x10-6 198.68±67.29 14.34±11.75
722.55 <1x10-6 122.60±42.17 9.37±5.57
848.64 <1x10-6 26.64±9.18 3.44±2
799.56 <1x10-6 90.11±32.72 7.11±5.92
800.56 <1x10-6 64.7±23.62 5.92±4.26
769.58 (SM) <1x10-6 94.32±34.4 9.06±5.37
828.57 <1x10-6 14.17±4.68 3.32±2.06
849.65 <1x10-6 13.13±4.42 2.93±2.09
770.56 <1x10-6 56.06±20.65 7.46±4.99
773.54 <1x10-6 50.43±18.96 5.18±3.47
755.58 (SM) <1x10-6 14.11±5.83 6.11±3.92
753.60 (SM) <1x10-6 70.94±31.10 10.69±7.62
771.57 (SM)  <1x10-6 27.07±10.97 6.23±2.62
783.79 (SM) <1x10-6 99.88±38.85 42.26±21.45
797.60 (SM) <1x10-6 17.00±6.60 10.27±3.59
GBT, glioma brain tissue; SD, standard deviation; SM, sphingomyelin; TBT, trauma brain tissue.
Table II. Lipid peaks with higher expression in GBT samples compared TBT samples.
Bio-marker (m/z) P-value Expression in TBT (mean ± SD) Expression in GBT (mean ± SD)
758.60 <1x10-6 11.31±4.45 142.89±64.64
759.60 (SM) <1x10-6 6.84±5.15 62.44±30.06
786.64 <1x10-6 11.49±5 88.97±43.94
808.60 <1x10-6 11.79±4.41 26.3±13.68
616.17 <1x10-6 23.52±26.34 264.5±274.96
617.07 <1x10-6 15.61±17.58 189.39±211.06
618.17 <1x10-6 6.52±5.76 70.8±82.58
614.16 <1x10-6 3.6±2.9 23.38±25.52
678.47 <1x10-6 2.91±1.34 22.32±13.36
703.43 (SM) <1x10-6 2.50±1.00 40.01±28.42
729.45 (SM) <1x10-6 3.28±1.60 16.56±8.60
731.48 (SM)  <1x10-6 18.51±15.14 85.24±45.36
741.54 (SM)  <1x10-6 7.82±4.55 10.49±5.70
757.57 (SM)  <1x10-6 12.39±4.88 19.34±7.93
781.59 (SM) <1x10-6 10.40±4.58 20.64±8.47
811.62 (SM)  <1x10-6 13.46±6.05 21.62±11.03
GBT, glioma brain tissue; SD, standard deviation; SM, sphingomyelin; TBT, trauma brain tissue.
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example, its expression intensity in normal control TBT 
samples was as high as 198.68, while its expression in GBT 
was decreased to 14.34.
Among these lipid peaks, the 758.60, 786.64, 617.07, 703.43 
and 731.48 m/z peaks exhibited markedly higher expression 
intensity in GBT samples compared with TBT samples. Taking 
the peak of 758.60 m/z as an example, its expression value in 
GBT was as high as 142.89, while its expression in normal 
control TBT was decreased to 11.31. Some of the differentially 
expressed lipid peaks in Tables I and II have the potential to 
serve as clinical diagnosis biomarkers for the detection and 
treatment of glioma.
Identification of lipid peaks. A total of 31 lipid peaks were 
detected using MALDI‑TOF‑MS, and 14 of these lipid peaks 
were identified as sphingomyelin (SM) using the second mass 
spectrum. These 14 peaks are listed and marked in Tables I and II 
with the label ‘SM’. The SM peak with the m/z value of 769.58 
had an intensity of 94.32 in TBT and the SM peak with the 
m/z value of 753.60 had an intensity of 70.94 in TBT (Table I). 
Table III shows the structural data for nine SM peaks.
Verif ication of the expression of lipid peaks with 
MALDI‑imaging. A total of 14 peaks were identified as SM. 
Due to the important role of SM in cell signal transduction, veri-
fication of the expression of SM peaks with MALDI‑imaging 
was performed. Fig. 1 shows the MALDI‑imaging results 
of four SM peaks. The sample patterns on the left are the 
MALDI-imaging results from TBT samples and the sample 
patterns on the right are the MALDI-imaging results from 
GBT samples. The expression intensities of the SM peaks with 
Figure 1. MALDI‑imaging results of sphingomyelin peaks in GBT and normal 
control TBT samples. MALDI‑imaging results of 741.54, 759.60, 769.58 and 
771.57 m/z are shown. GBT, glioma brain tissue; TBT, trauma brain tissue.
Figure 2. Distribution of ceramide and IGF‑1R on the cell membrane. 
(A) Distr ibution of ceramide was obtained by immunostaining. 
(B) Distribution of IGF‑1R was obtained by live staining. IGF‑1R, insulin‑like 
growth factor‑1 receptor. Scale bar, 50 µm.
Figure 3. Movement of IGF‑1R. The distribution status of IGF‑1R on the cell 
membrane was recorded by live staining technology. The movement track of 
IGF‑1R can be observed with the laser scanning confocal microscopy at 0, 5, 
10 and 20 min. IGF‑1R, insulin‑like growth factor‑1 receptor. Scale bar, 50 µm.
Figure 4. Expression of IGF‑1R on the cell surface. The immunostaining 
results of two groups of glioma U373-MG cells are shown. Cells in the two 
groups were treated with insulin. The influence of drug Desi on IGF‑1R 
expression was observed by comparing the two groups. Desi, desipramine; 
IGF‑1R, insulin‑like growth factor‑1 receptor. Scale bar, 50 µm.
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m/z values of 769.58, 771.57, 797.60, 783.79 and 753.60 were 
higher in the normal control TBT samples compared with in 
the GBT samples. The expression intensities of the SM peaks 
with m/z values of 741.54, 781.59, 759.60, 757.57, 731.48 and 
703.43 were higher in GBT samples compared with in normal 
control TBT samples. The results of the MALDI-imaging 
experiments were consistent with the expression intensity 
results from the MALDI‑TOF‑MS experiments.
Regulation and control of the expression properties of 
insulin‑like growth factor‑1 receptor (IGF‑1R) and the 
PI3K/AKT pathway. Firstly, SM biomarkers, which were 
differentially expressed between GBT and TBT samples, 
were identified. Subsequently, the regulation of IGF‑1R and 
the PI3K/AKT pathway by ceramide were investigated. The 
regulatory effect of ceramide on IGF‑1R and the PI3K/Akt 
pathway was investigated using the glioma cell line U373-MG.
Distribution of ceramide and IGF‑1R on the cell membrane. 
The distribution characteristics of ceramide and IGF‑1R on 
the cell membrane were observed by immunostaining. Fig. 2A 
shows the distribution of ceramide, as revealed by immunos-
taining. It was identified that ceramide was made up of lipid 
rafts, and large quantities of ceramide aggregated to form 
an areatus‑like distribution. Fig. 2B shows the live staining 
pattern of IGF‑1R relative to ceramide. It was revealed that 
IGF‑1R formed an areatus‑like distribution that was similar to 
the distribution of ceramide.
Observation of the movement of IGF‑1R with live staining tech‑
nology. The movement of IGF‑1R, a ceramide receptor (19), on 
the cell membrane was recorded with live staining technology. 
Fig. 3 illustrates the movement of IGF‑1R, as visualized 
with live cell staining technology. The cell dish was placed 
into a CO2 incubator and observed via confocal microscopy 
at 37˚C with 5% CO2. The recording times were 0, 5, 10 and 
20 min. At 0 min, IGF‑1R fluorescence was observed on the 
cell membrane, whereas IGF‑1R fluorescence in the inner area 
of some cells was not clear. As the recording time increased, 
the IGF‑1R fluorescence in the inner area of cells increased. 
When the recording time reached 20 min, the inner area of 
numerous cells presented high fluorescence intensity. IGF‑1R 
fluorescence was indicated with arrows in Fig. 3.
Regulation of the expression of IGF‑1R. Data from Fig. 4 
indicated that the expression level of phosphorylated IGF‑1R 
was markedly stimulated by insulin when the glioma cell line 
Table III. Structural data of various sphingomyelin peaks.
Biomarker (m/z) Common name Chemical composition
741.54 SM(d18:1/16:0) [C39H79N2O6P+K] 1+
755.58  SM(d18:1/17:0) [C40H81N2O6P+K] 1+
757.57  SM(d18:0/17:0) [C40H83N2O6P+K] 1+
769.58 SM(d18:1/18:0) [C41H83N2O6P+K] 1+
771.57 SM(d18:0/18:0) [C41H85N2O6P+K] 1+
797.60  SM(d18:1/20:0) [C43H87N2O6P+K] 1+
811.62  SM(d16:1/23:0) [C44H89N2O6P+K] 1+
783.79  SM(d18:1/19:0) [C42H85N2O6P+K] 1+
729.45 SM(d18:0/15:0) [C38H79N2O6P+K] 1+
Figure 5. Expression levels of proteins associated with the PI3K/Akt pathway. Western blotting results of phosphorylated and total Src, S6k and Akt levels. 
U373‑MG cells were treated with insulin for 0, 15, 30 and 60 min. One group of cells was treated with DMSO while the other group was treated with Desi. P‑, 
phosphorylated‑; S6k, ribosomal protein S6 kinase B1; Src, SRC proto‑oncogene non‑receptor tyrosine kinase; T‑, total‑; Desi, desipramine.
Figure 6. Western blotting quantitative result for P‑Akt.  U373‑MG cells were 
treated with insulin for 0, 15, 30 and 60 min. One group of cells was treated 
with DMSO whereas the other group was treated with Desi. Desi, desipramine.
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U373-MG was treated with DMSO as a control. Compared 
with the f luorescence intensity at 0 min in the DMSO 
group and the fluorescence intensity at 0 min in the Desi 
group, the expression level of phosphorylated IGF‑1R was 
significantly decreased when U373‑MG cells were treated 
with Desi. In the DMSO group, the fluorescence intensity 
of phosphorylated IGF‑1R was higher when the cells were 
stimulated with insulin for 30 min. In the Desi group, the 
fluorescence intensity of phosphorylated IGF‑1R was not 
markedly increased when cells were further stimulated with 
insulin for 30 min.
Regulation of the PI3K/Akt pathway. Results on the PI3K/Akt 
pathway regulation are presented in Fig. 5. The expression 
intensity of phosphorylated-(P-)Akt, P-SRC proto-oncogene 
non-receptor tyrosine kinase (Src) and P-ribosomal protein S6 
kinase B1 (S6k) in DMSO group increased gradually with 
increasing time of treatment with insulin. Furthermore, 
the influence of insulin in Desi group was weakened by the 
application of Desi. Taking the P-Akt as an example, its quan-
titative result is shown in Fig. 6. The relative intensity of P‑Akt 
in group DMSO at 0 min is 0.70, while that in group Desi 
decreases to 0.16. Furthermore, the relative intensity of P‑Akt 
in group Desi are less than that in group DMSO at 15, 30 and 
60 min.
Discussion
In the present study, MALDI‑imaging and MALDI‑TOF‑MS 
were used to investigate the differences in the expression 
levels of lipid biomarkers in GBT and TBT samples. A total 
of 31 lipid peaks with differential expression properties were 
detected in the GBT and TBT samples. A total of 15 lipid 
peaks exhibited higher expression intensity in TBT compared 
with GBT samples. Furthermore, 14 lipid peaks were 
identified as sphingomyelin peaks. As previously reported, 
sphingomyelin can be hydrolyzed into ceramide via acid 
sphingomyelinase (ASM) (20,21).The results demonstrated 
that ceramide and IGF‑1R had similar membrane distribu-
tion. The live cell staining results indicated that IGF‑1R 
slowly entered the cell from the cell membrane, resulting 
in increased IGF‑1R fluorescence in the inner area of cell. 
These results were in accordance with a previous study that 
reported that ceramide can bind to IGF‑1R and is involved 
in cell signal transduction (22). The drug Desi was able to 
inhibit the accumulation of ceramide on the cell membrane. 
Insulin was able to stimulate IGF‑1R expression, although 
IGF‑1R expression was inhibited by treatment with Desi. 
Similar results were also observed for the expression levels of 
proteins P-Src, P-Akt and P-S6k from the PI3K/Akt signaling 
pathway. Previous studies reported that the dysregulation of 
the IGF‑1R signaling pathway results in the development of 
malignant gliomas (19,23,24). In addition, glioma cell senes-
cence and apoptosis can be influenced by the activity of the 
PI3K/Akt signaling pathway (25,26).
Due to the difficulty of obtaining brain tissues, only three 
GBT samples and three normal control TBT samples were 
collected and used in the present study. For MALDI‑imaging, 
it is advantageous to obtain cancer tissues and normal tissues 
from the same individual; however, it is difficult to perform 
experiments on glioma tissue and normal brain tissue from the 
same person. Therefore, the brain tissues for glioma research 
were usually collected from different individuals (27-29). The 
results of the present study were based on a limited sample 
size, and the findings would be more valuable and reliable 
if they were based on a larger sample size. These first‑stage 
results may serve as the research foundation for further 
studies. There are several topics requiring further investiga-
tion, including how the opposite alterations in the same type 
of lipid biomarkers may be used to form a diagnostic pattern 
for patients with glioma. Additionally, it should be investigated 
how to predict the functional effect of these differentially 
expressed lipid biomarkers between GBT and normal TBT by 
pathway enrichment analysis. In the future, these issues will be 
addressed in a study with a larger sample size.
In conclusion, the present study demonstrated that sphingo-
myelin peaks may be identified as biomarkers in GBT samples 
compared with normal control TBT samples. Furthermore, 
insulin could stimulate the high expression of ceramide and 
of P-Akt from the PI3K/Akt signaling pathway. However, 
Desi inhibited the increase in ceramide and P-Akt expression. 
Future study will investigate the association between these 
sphingomyelins and the survival rate of patients with glioma, 
and the expression intensity variation of these sphingomyelin 
along with the clinical treatment process of patients with 
glioma.
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